{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:52:02Z","timestamp":1780667522475,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.critrevonc.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T14:00:56Z","timestamp":1521468056000},"page":"84-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors"],"prefix":"10.1016","volume":"125","author":[{"given":"Mohd","family":"Wahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Jawed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju K.","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad A.","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Somvanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohtashim","family":"Lohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Y.","family":"Areeshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafiul","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.critrevonc.2018.03.005_bib0005","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.03.005_bib0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00280-006-0323-5","article-title":"Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration","volume":"59","author":"Brown","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.03.005_bib0015","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1586\/14737140.2015.1060127","article-title":"Trametinib in metastatic melanoma","volume":"15","author":"Chopra","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0020","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2018.03.005_bib0035","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.03.005_bib0040","first-page":"989","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favourable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Cancer Ther. Preclin."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.03.005_bib0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2018.03.005_bib0055","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-09-0679","article-title":"RDEA119\/BAY 869766: a potent, selective, allosteric inhibitor of MEK1\/2 for the treatment of cancer","volume":"69","author":"Iverson","year":"2009","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2018.03.005_bib0060","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0065","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.03.005_bib0070","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.03.005_bib0075","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2217\/fon.14.89","article-title":"Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma","volume":"10","author":"King","year":"2014","journal-title":"Future Oncol."},{"issue":"12 Suppl. 1","key":"10.1016\/j.critrevonc.2018.03.005_bib0080","article-title":"Abstract B88: a selective RAF kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RAFV600E mutation [abstract]","volume":"8","author":"Laquerre","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0085","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0090","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.critrevonc.2018.03.005_bib0095","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","article-title":"Phase I and pharmacodynamics study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies","volume":"23","author":"LoRusso","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0100","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.03.005_bib0110","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-11-2612","article-title":"The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms","volume":"18","author":"Paraiso","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.12788\/jcso.0014","article-title":"Dabrafenib in advanced melanoma with BRAF V600E mutation","volume":"12","author":"Stenger","year":"2014","journal-title":"JCSO"},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0130","series-title":"Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research","article-title":"Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion","author":"Straussman","year":"2012"},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0135","unstructured":"Tafinlar. http:\/\/www.rxlist.com\/tafinlar-drug\/clinical-pharmacology.htm. (Assessed on 15.05.2017)."},{"key":"10.1016\/j.critrevonc.2018.03.005_bib0140","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/0008-5472.CAN-13-1633","article-title":"The evolution of melanoma resistance reveals therapeutic opportunities","volume":"73","author":"Thakur","year":"2013","journal-title":"Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281730481X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281730481X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:53:53Z","timestamp":1534985633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281730481X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":28,"alternative-id":["S104084281730481X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.03.005","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}